Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions | ||
By: Nasdaq / GlobeNewswire - 23 Jun 2018 | Back to overview list |
|
Press Release - No. 16/2018 Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions
Copenhagen and Boston, June 23, 2018 - Zealand Pharma ("Zealand") and T1D Exchange announce today that Dr. Morey Haymond, MD, Baylor College of Medicine, Houston, TX, U.S. will present the results of a Zealand Pharma supported T1D Exchange survey "Use of Glucagon in Patients with Type 1 Diabetes" at the American Diabetes Association's 78th Scientific Sessions in Orlando, FL, U.S. held June 22-26 2018. The survey investigated the use of glucagon rescue kits in the treatment of severe hypoglycemia and revealed major underuse: A total of 349 participants including T1D Exchange patients and caregivers, were enrolled via myGlu.org or the T1D Exchange Registry and completed a 30 min online questionnaire to assess the perceptions and experiences using currently available glucagon rescue kits. Dr. Morey Haymond, MD, Baylor College of Medicine, Houston commented: "The T1D Exchange survey highlights the difficulties with handling the current glucagon rescue kits when patients are experiencing severe hypoglycemia. The data also suggest a significant underutilization of current glucagon rescue kits and the need for more education for prescribers, patients and caregivers, as severe hypoglycemia remains one of the biggest fears among patients treated with insulin. A stable ready-to-use form of glucagon and an easy-to-use device for its administration would dramatically improve the safety and efficacy of it use in patients with severe hypoglycemia". Alicia McAuliffe-Fogarty, PhD. T1D Exchange, Boston commented: "Glucagon can be a lifesaving tool for all people with people type 1 diabetes. Yet, this research shows that glucagon is underused and under prescribed. We advocate that education about the use and administration of glucagon--as well as a yearly prescription--should be a standard of care." Adam Steensberg, MD, Executive Vice President, Chief Medical and Development Officer of Zealand commented: "I believe that the results presented today highlight the need for more education on the risks of severe hypoglycemia for diabetes patients on insulin treatment. There are several novel ready-to-use treatments in development for severe hypoglycemia, including Zealand Pharma's HypoPal® rescue pen, which may in the future contribute to better patient care." For further information, please contact: Zealand Pharma T1D Exchange About Zealand Pharma A/S About T1D Exchange About HypoPal® rescue pen for severe hypoglycemia Attachment |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |